Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain UTHR message board posts where the ticker symbol UTHR has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest UTHR SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-022973 Size: 8 KB
2018-07-09
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-022919 Size: 7 KB
2018-07-06
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-022918 Size: 7 KB
2018-07-06
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-022828 Size: 8 KB
2018-07-05
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-022040 Size: 4 KB
2018-06-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-021996 Size: 5 KB
2018-06-28
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-021994 Size: 12 KB
2018-06-28
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-021989 Size: 12 KB
2018-06-28
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-021988 Size: 9 KB
2018-06-28
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001127602-18-021987 Size: 9 KB
2018-06-28
More UTHR SEC Filings


Related news from
Mon, 25 Jun 2018
11:30:00 +0000
Factors of Influence in 2018, Key Indicators and Opportunity within Dr Pepper Snapple Group, United Therapeutics, Universal Health Realty Income Trust, Forestar Group, Schlumberger, and Thermo Fisher Scientific — New Research Emphasizes Economic Growth
NEW YORK, June 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dr ...
Sat, 23 Jun 2018
13:08:05 +0000
Is United Therapeutics Corporation’s (NASDAQ:UTHR) ROE Of 20.42% Sustainable?
This article is intended for those of you who are at the beginning of your investing journey and want to begin learning the link between United Therapeutics Corporation (NASDAQ:UTHR)’s returnRead More...
Tue, 19 Jun 2018
20:35:43 +0000
United Therapeutics CEO: Going public was my biggest mistake
United Therapeutics CEO Martine Rothblatt shared her biggest mistake at the Forbes Women's Summit in NYC.
Tue, 12 Jun 2018
05:30:00 +0000
United Therapeutics And XVIVO Perfusion Announce Collaboration To Reduce Organ Shortage Through Expansion Of Organ Evaluation Service
SILVER SPRING, Md. and ENGLEWOOD, Colo., June 12, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR) and XVIVO Perfusion, Inc., a subsidiary of XVIVO Perfusion AB (XVIVO.ST), today announced that the use of XVIVO's ex-vivo lung perfusion (EVLP) technology will be incorporated into the Silver Spring, Maryland laboratory of Lung Bioengineering Inc., a subsidiary of United Therapeutics' public benefit corporation subsidiary Lung Biotechnology PBC. "I am excited about trying to make more life-saving use of donated lungs via XVIVO Perfusion's pioneering technology," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "United Therapeutics' impressive history of developing and delivering innovative and effective therapies for severe lung diseases makes them the ideal partner for XVIVO Perfusion in our quest to prevent mortality due to organ shortages," said Dr. Magnus Nilsson, Chief Executive Officer of XVIVO Perfusion.
Fri, 08 Jun 2018
11:00:00 +0000
TG Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space
LONDON, UK / ACCESSWIRE / June 08, 2018 / If you want a free Stock Review on TGTX sign up now at www.wallstequities.com/registration. This Friday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: TG Therapeutics Inc. (NASDAQ: TGTX), Trevena Inc. (NASDAQ: TRVN), United Therapeutics Corp. (NASDAQ: UTHR), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA).
Wed, 06 Jun 2018
22:18:19 +0000
Should You Buy United Therapeutics Corporation (NASDAQ:UTHR) At This PE Ratio?
United Therapeutics Corporation (NASDAQ:UTHR) is currently trading at a trailing P/E of 9.8x, which is lower than the industry average of 26.5x. While this makes UTHR appear like a greatRead More...
Wed, 06 Jun 2018
20:03:27 +0000
Drugmaker Lundbeck to settle U.S. charity probe for $52.6 mln
Danish drugmaker Lundbeck said on Wednesday that it will pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations. The company, formally called H. Lundbeck A/S, said it had reached an agreement with the U.S. Justice Department, which has investigating drugmakers' support of charities that help Medicare patients cover out-of-pocket drug costs. Lundbeck, which develops and distributes drugs for neurological and psychological diseases such as depression and Alzheimer's, said the settlement would include no admission of wrongdoing and is subject to further negotiation.
Fri, 01 Jun 2018
13:34:01 +0000
United Therapeutics (UTHR) Up 3.9% Since Earnings Report: Can It Continue?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Thu, 31 May 2018
14:45:00 +0000
CORV: Cipher Transaction Done; Focus Back to Europe
During the first quarter and to date, Correvio announced a strategic transaction with Cipher (CPH.TO) and subsequently closed it, changing their name and ticker symbol in the process. Importantly, as part of the transaction with Cipher, Correvio has received about US$20 million, which should provide sufficient capital to achieve operationally breakeven levels. Sales, general and administrative expenses were $10.9 million, increasing 33% as the company increased the size of its European direct sales force and the recognition of business development and transaction costs related to the Cipher transaction.
Tue, 29 May 2018
11:32:20 +0000
How Did Merck’s Cardiovascular Segment Perform in Q1 2018?
Merck & Company’s (MRK) Zetia (ezetimibe) reported revenue of $305 million in Q1 2018 compared to $334 million in Q1 2017, a ~9% fall YoY (year-over-year) and a ~6% fall sequentially.
Sun, 27 May 2018
10:32:00 +0000
3 Healthcare Stocks That Are Undeniably Dirt Cheap Right Now
These stocks are definitely inexpensive. But are they buys?
Mon, 21 May 2018
18:44:50 +0000
Maryland Commerce Department's Preakness guest list includes Amazon, Marriott execs
The Department of Commerce spent $50,000 on the Preakness, consistent with previous years.
Tue, 15 May 2018
12:00:00 +0000
SteadyMed Provides Corporate Update and Reports First Quarter 2018 Financial Results
SAN RAMON, Calif., May 15, 2018-- SteadyMed Ltd., a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral ...
Wed, 09 May 2018
12:05:49 +0000
See what the IHS Markit Score report has to say about United Therapeutics Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Wed, 09 May 2018
03:12:48 +0000
Analysts: Generic drugs won’t affect United Therapeutics ‘that much’
The Silver Spring biotech is seeing patents expire on some of its key drugs, a longstanding problem. But two analysts say it may not be as bad as it appears.
Wed, 09 May 2018
00:53:37 +0000
Jazz Pharmaceuticals to settle U.S. probe for $57 million
Jazz Pharmaceuticals Plc said on Tuesday it had agreed to pay $57 million to resolve a U.S. probe into its financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs. The drugmaker said in a filing with the U.S. Securities and Exchange Commission that it reached an agreement in principle with the U.S. Justice Department to pay the sum as part of a civil settlement. Jazz, which produces the expensive narcolepsy drug Xyrem, said in the filing it could not guarantee its efforts to reach a final settlement would be successful.
Tue, 08 May 2018
09:00:00 +0000
Md. biotech to be acquired by New Jersey pharmaceutical goliath
The final price, a bit more than a billion dollars, includes upfront cash and payments based on achieving certain milestones.
Mon, 07 May 2018
14:02:19 +0000
Top 3 Undervalued Stocks For The Month
Jerash Holdings (US) and United Therapeutics are stocks on my list that are potentially undervalued. This means their current share prices are trading well-below what the companies are actually worth.Read More...
Fri, 04 May 2018
20:06:08 +0000
Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication
Earnings are in focus this week with Pfizer (PFE) and Merck (MRK) delivering mixed Q1 numbers. Novartis gains FDA approval for the second indication of its CAR-T therapy, Kymriah.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum is the gold standard, valuable because of the exceptional people who post here, and because the best of them are candid, detailed and informed. There is little tolerance for the b.s. found on public boards, and management and members are vigilant and aggressive about TOS violations. VF is the gold standard." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards